Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
WESTON, Fla., May 18, 2015 -- Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced that an abstract revealing new data for Cantex's lead compound, CX-01, has been selected for a poster presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29 to June 2, 2015, in Chicago.
The poster, titled O-Desulfated Heparin and Chemotherapy for the Treatment of AML, reported results of a study that combined ODSH (CX-01) with chemotherapy for the treatment of acute myeloid leukemia (AML). The poster will be presented by Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute, during the "Leukemia, Myelodysplasia, and Transplantation" session on Sunday, May 31, 8:00 AM, CT to 11:30 AM, CT; Poster Board #42; Abstract #7053.
CX-01 is currently in clinical development for acute myeloid leukemia, pediatric solid tumors, and lung cancer. The drug is designed to block the activity of chemokines that support the growth and spread of cancer and its resistance to treatment and that contribute to the delay of bone marrow recovery after chemotherapy. Chemokines have emerged as major cancer targets because of the central role they play in facilitating cancer cell growth and metastasis and in the resistance of cancer cells to the cell-killing effects of chemotherapy and radiation. Among these chemokines are CXCR4 and CXCL12, which are critical to the migration and attachment of cancer cells to the protective bone marrow environment as well as to metastatic sites, and CXCL4, which slows bone marrow recovery after chemotherapy.
Stephen Marcus, M.D., president of Cantex Pharmaceuticals, commented, "We are very pleased to have the opportunity to present data on our lead product, CX-01, during ASCO 2015. Clinical and pre-clinical studies have indicated the potential of CX-01 to significantly increase the responsiveness of cancer to treatment, while, at the same time, accelerating platelet and white blood cell recovery when administered in conjunction with chemotherapy. Based on the data to be presented during ASCO 2015, as well as our prior clinical and preclinical studies of CX-01, Cantex expects to soon initiate randomized clinical trials of CX-01 in acute myeloid leukemia and lung cancer."
Full abstracts of corporate and collaborator presentations can be accessed on the ASCO website at abstracts.asco.org.
About Cantex Pharmaceuticals
Cantex Pharmaceuticals is a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment. The Company's lead product candidate, CX-01, is in clinical development for acute myeloid leukemia and lung cancer. CX-01 is a rationally designed complex carbohydrate that blocks the activity of several chemokines that support the growth and spread of cancer and its resistance to treatment and that contribute to the delay of bone marrow recovery after chemotherapy. For more information, please visit www.cantex.com.